Literature DB >> 14506831

A novel type hypertriglyceridemia observed in FLS mice.

Masaya Takahashi1, Toshiji Saibara, Yoshihisa Nemoto, Masafumi Ono, Naoaki Akisawa, Shinji Iwasaki, Katsumi Toda, Yasuhiro Ogawa, Akihiko Wakatsuki, Shuichiro Inagaki, Saburo Onishi.   

Abstract

The unique inborn hypertriglyceridemia seen in FLS (fatty liver Shionogi) mice was relieved by the administration of purified apolipoprotein (apo) C-II. Lipoprotein lipase (LPL) and its cofactor, apoC-II, play a pivotal role in VLDL metabolism. Therefore, we investigated the genetic background involved in this hypertriglyceridemia. Plasma levels of TG and total cholesterol as well as LPL activity were measured in male FLS mice and C57/BL6J mice. Agarose gel electrophoresis and fast protein liquid chromatography were used to analyze the lipoprotein profile. A cross experiment was done to determine the genetic background of hypertriglyceridemia observed in FLS mice. cDNA sequences of apoC-II and apoC-III of FLS mice were determined. Prealpha-lipoprotein was the predominant lipoprotein class in FLS mouse plasma. LPL activity remained in the range observed in C57/BL6J mice, and purified apoC-II transiently relieved FLS mice from hypertriglyceridemia. Prealpha-lipoproteinemia was inherited in an autosomal recessive manner. ApoC-III appeared to be a causal factor for this unique hypertriglyceridemia. Microsatellite analysis, however, revealed that the responsible chromosome was not 7; rather, apoC-III mapped onto chromosome 9. Therefore, we suggest apoC-III as a candidate causative factor for the hypertriglyceridemia observed in FLS mice because an excessive amount of apoC-III attenuates LPL activity in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506831     DOI: 10.1007/s11745-003-1116-7

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  27 in total

1.  Isoelectric heterogeneity of the cofactor protein for lipoprotein lipase in human blood plasma.

Authors:  R J Havel; L Kotite; J P Kane
Journal:  Biochem Med       Date:  1979-02

Review 2.  The plasma lipoproteins: structure and metabolism.

Authors:  L C Smith; H J Pownall; A M Gotto
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

3.  Effect of tamoxifen on serum lipid metabolism.

Authors:  Y Hozumi; M Kawano; T Saito; M Miyata
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

4.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

5.  On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.

Authors:  S Eisenberg; D W Bilheimer; R I Levy; F T Lindgren
Journal:  Biochim Biophys Acta       Date:  1973-12-20

6.  A specific apoprotein activator for lipoprotein lipase.

Authors:  J C LaRosa; R I Levy; P Herbert; S E Lux; D S Fredrickson
Journal:  Biochem Biophys Res Commun       Date:  1970-10-09       Impact factor: 3.575

7.  Apolipoprotein C-II deficiency associated with nonfunctional mutant forms of apolipoprotein C-II.

Authors:  G F Maguire; J A Little; G Kakis; W C Breckenridge
Journal:  Can J Biochem Cell Biol       Date:  1984-09

8.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

9.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

10.  Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.

Authors:  W C Breckenridge; J A Little; G Steiner; A Chow; M Poapst
Journal:  N Engl J Med       Date:  1978-06-08       Impact factor: 91.245

View more
  1 in total

1.  Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse Model.

Authors:  Ran Nagahara; Tomomitsu Matono; Takaaki Sugihara; Yukako Matsuki; Masafumi Yamane; Toshiaki Okamoto; Kenichi Miyoshi; Takakazu Nagahara; Jun-Ichi Okano; Masahiko Koda; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.